Jeffrey Arcara - Corvus Pharmaceuticals Chief Officer
| CRVS Stock | USD 8.93 0.02 0.22% |
Executive
Jeffrey Arcara is Chief Officer of Corvus Pharmaceuticals
| Address | 863 Mitten Road, Burlingame, CA, United States, 94010 |
| Phone | 650 900 4520 |
| Web | https://www.corvuspharma.com |
Jeffrey Arcara Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Arcara against Corvus Pharmaceuticals stock is an integral part of due diligence when investing in Corvus Pharmaceuticals. Jeffrey Arcara insider activity provides valuable insight into whether Corvus Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Corvus Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Corvus Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Arcara over six months ago Acquisition by Jeffrey Arcara of 400000 shares of Corvus Pharmaceuticals at 2.3 subject to Rule 16b-3 | ||
Jeffrey Arcara over six months ago Acquisition by Jeffrey Arcara of 400000 shares of Corvus Pharmaceuticals at 2.3 subject to Rule 16b-3 |
Corvus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2383) % which means that it has lost $0.2383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4491) %, meaning that it created substantial loss on money invested by shareholders. Corvus Pharmaceuticals' management efficiency ratios could be used to measure how well Corvus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.62 in 2024. Return On Capital Employed is likely to drop to -0.63 in 2024. At this time, Corvus Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 72.5 M in 2024, whereas Other Current Assets are likely to drop slightly above 687.3 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Spencer JD | PDS Biotechnology Corp | 54 | |
| Deanne Randolph | PDS Biotechnology Corp | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Michael Szumera | Hookipa Pharma | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| Daniel Courtney | Hookipa Pharma | N/A | |
| MS MBA | PDS Biotechnology Corp | 58 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Roman Necina | Hookipa Pharma | 56 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 |
Corvus Pharmaceuticals Leadership Team
Elected by the shareholders, the Corvus Pharmaceuticals' board of directors comprises two types of representatives: Corvus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corvus. The board's role is to monitor Corvus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Corvus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corvus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leiv Lea, Chief Officer | ||
| James MD, Senior Research | ||
| Alan Esq, Sec | ||
| MD FACP, CoFounder Director | ||
| William Jones, Vice President of Pharmaceutical Development | ||
| Erik Verner, Vice President of Chemistry Research | ||
| Jeffrey Arcara, Chief Officer | ||
| Richard MD, President, CoFounder |
Corvus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corvus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 532.52 M | ||||
| Shares Outstanding | 64.26 M | ||||
| Shares Owned By Insiders | 4.02 % | ||||
| Shares Owned By Institutions | 44.47 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | (5.64) X | ||||
| Price To Book | 46.24 X | ||||
| EBITDA | (26.88 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corvus Stock Analysis
When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.